| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
Entadamide-A-β-D-glucopyranoside targets the complement system, a part of the immune system that enhances the ability of antibodies and phagocytic cells to clear pathogens and damaged cells. By inhibiting complement activation, the compound may modulate inflammatory responses and reduce tissue damage associated with excessive complement activation. The compound also exhibits antimicrobial activity, suggesting additional targets in bacterial pathogens. Its anti-inflammatory and analgesic functions indicate potential involvement in pain and inflammatory pathways.
|
|---|---|
| ln Vitro |
In vitro, Entadamide-A-β-D-glucopyranoside demonstrates significant anti-complement activity, which is typically assessed by measuring inhibition of complement-mediated hemolysis or complement component deposition. The compound also displays significant inhibitory effects on gram-positive and gram-negative bacteria, indicating broad-spectrum antimicrobial activity. These activities suggest that the compound may have potential applications in immune modulation and infectious disease research. Specific IC50 or MIC values are not detailed in the available literature.
|
| ln Vivo |
Specific in vivo data for Entadamide-A-β-D-glucopyranoside are limited. Given its anti-complement and anti-inflammatory activities, the compound could potentially be studied in animal models of complement-mediated diseases such as autoimmune disorders, ischemia-reperfusion injury, or inflammatory conditions. Its antimicrobial activity suggests potential for in vivo efficacy studies in infection models. However, specific published in vivo protocols for this compound are not available in the current literature.
|
| Enzyme Assay |
The anti-complement activity is assessed using a hemolytic assay. Sheep erythrocytes are sensitized with anti-sheep erythrocyte antibodies (hemolysin) to activate the classical complement pathway. Various concentrations of Entadamide-A-β-D-glucopyranoside are incubated with guinea pig serum (as a source of complement) and sensitized erythrocytes. The degree of hemolysis is measured spectrophotometrically at 412 nm, and the inhibition of complement activity is calculated by comparing to control samples without the compound.
|
| Cell Assay |
For antimicrobial testing, bacterial strains (gram-positive and gram-negative) are cultured in appropriate broth media. Entadamide-A-β-D-glucopyranoside is added at various concentrations, and bacterial growth is monitored by measuring optical density at 600 nm or by colony counting on agar plates after incubation. The minimum inhibitory concentration (MIC) is determined as the lowest concentration that inhibits visible growth. For anti-inflammatory studies, immune cells such as macrophages may be treated with the compound and stimulated with LPS, with cytokine levels measured by ELISA.
|
| Animal Protocol |
In vivo studies for Entadamide-A-β-D-glucopyranoside would be conducted in appropriate animal models. For anti-complement or anti-inflammatory studies, models such as carrageenan-induced paw edema, zymosan-induced peritonitis, or complement-mediated disease models could be employed. The compound would be administered via oral gavage, intraperitoneal injection, or intravenous injection, and endpoints would include inflammatory markers, tissue histopathology, and clinical scores. For antimicrobial studies, infection models using relevant pathogens would be used. However, specific published protocols are not available.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for Entadamide-A-β-D-glucopyranoside are not reported. As a glucoside with molecular weight 323.36 g/mol, the compound's oral bioavailability may be limited due to poor membrane permeability and potential hydrolysis by intestinal glycosidases. Its water solubility (309.25 mM) suggests good aqueous solubility for formulation. Pharmacokinetic studies would be required to determine absorption, distribution, metabolism, and excretion parameters in animal models.
|
| Toxicity/Toxicokinetics |
Toxicological data for Entadamide-A-β-D-glucopyranoside are limited. As a natural product from Entada phaseoloides, which has traditional medicinal uses, the compound is generally considered to have a moderate safety profile. However, systematic toxicology studies have not been reported. The compound should be handled with appropriate safety precautions in laboratory settings. Comprehensive toxicological evaluations would be required before any potential therapeutic development.
|
| References | |
| Additional Infomation |
Entamamide-A-|AD-glucopyranoside has been reported and data are available.
Entadamide-A-β-D-glucopyranoside is a glucoside from Entada phaseoloides seeds with anti-complement activity, antimicrobial effects against gram-positive and gram-negative bacteria, and anti-inflammatory/analgesic functions. It is used in research on immune modulation and infectious diseases. No clinical trials or approvals exist. For research use only. |
| Molecular Formula |
C12H21NO7S
|
|---|---|
| Molecular Weight |
323.363
|
| Exact Mass |
323.103
|
| CAS # |
138916-58-2
|
| PubChem CID |
101616680
|
| Appearance |
White to off-white solid powder
|
| LogP |
-2
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
21
|
| Complexity |
355
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
CSC=CC(=O)NCCOC1C(C(C(C(O1)CO)O)O)O
|
| InChi Key |
FISKBHZVUFLWDZ-IYYAVIMFSA-N
|
| InChi Code |
InChI=1S/C12H21NO7S/c1-21-5-2-8(15)13-3-4-19-12-11(18)10(17)9(16)7(6-14)20-12/h2,5,7,9-12,14,16-18H,3-4,6H2,1H3,(H,13,15)/b5-2+/t7-,9-,10+,11-,12-/m1/s1
|
| Chemical Name |
(E)-3-methylsulfanyl-N-[2-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyethyl]prop-2-enamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~309.25 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.73 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.73 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.73 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0925 mL | 15.4626 mL | 30.9253 mL | |
| 5 mM | 0.6185 mL | 3.0925 mL | 6.1851 mL | |
| 10 mM | 0.3093 mL | 1.5463 mL | 3.0925 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
